Alexa B. Kimball

28.4k citations
374 papers · 18.4k · 11 hit papers · h-index 66

Impact in

  • Dermatology top 0.01%
    • Dermatology and Skin Diseases
    • Hidradenitis Suppurativa and Treatments
    • Acne and Rosacea Treatments and Effects
  • Immunology top 0.1%
    • Psoriasis: Treatment and Pathogenesis

Papers in

    • Hidradenitis Suppurativa and Treatments 101
    • Dermatology and Skin Diseases 34
    • Acne and Rosacea Treatments and Effects 22
    • Chemotherapy-related skin toxicity 22
    • Skin Protection and Aging 17
    • Psoriasis: Treatment and Pathogenesis 111

Alexa B. Kimball

357 papers receiving 17.7k citations

Alexa B. Kimball's Hit Papers

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials 2024 · 87 citations
870+6+13Years since publication50010001.5k

Peers

Alexa B. Kimball
Comparison fields: 5 of 175
  • Dermatology 8.1k
  • Immunology 8.8k
  • Rheumatology 1.7k
  • Complementary and Manual Therapy 221
  • Pathology and Forensic Medicine 1.3k
Replace Matthias Augustin with:
Matthias Augustin Germany
L. Puig Spain
April W. Armstrong United States
Joel M. Gelfand United States
Alan Menter United States
Tamar Nijsten Netherlands
Lone Skov Denmark
John Koo United States
Kristian Reich Germany
Jacek C. Szepietowski Poland
Alexa B. Kimball relative to Matthias Augustin Germany Matthias Augustin's profile →
Citations per field
00.5×1.5×
Matthias Augustin · 1×
Citations per year

Countries citing papers authored by Alexa B. Kimball

Since Specialization
Citations

This map shows the geographic impact of Alexa B. Kimball's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexa B. Kimball with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexa B. Kimball more than expected).

Fields of papers citing papers by Alexa B. Kimball

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexa B. Kimball. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexa B. Kimball. The network helps show where Alexa B. Kimball may publish in the future.

Co-authors

The 25 scholars most cited alongside Alexa B. Kimball, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alexa B. Kimball Line = papers co-authored together Alexa B. Kimball links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 374 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Hit paper breakdown →
20081502
2
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Hit paper breakdown →
2007711
3
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Hit paper breakdown →
2017658
4
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis
Hit paper breakdown →
2006587
5 2005447
6
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
Hit paper breakdown →
2017432
7
Hidradenitis suppurativa
Hit paper breakdown →
2020390
8 2008355
9
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Hit paper breakdown →
2012312
10 2013256
11
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations
Hit paper breakdown →
2019241
12
North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations
Hit paper breakdown →
2019238
13 2002235
14 2014231
15 2011225
16 2010204
17 2008189
18 2010188
19 2003178
20 2018178

About Alexa B. Kimball

Alexa B. Kimball is a scholar working on Dermatology, Immunology, Surgery, Public Health, Environmental and Occupational Health and Epidemiology, having authored 374 papers that have together received 18.4k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (111 papers), Hidradenitis Suppurativa and Treatments (101 papers), Colorectal and Anal Carcinomas (52 papers), Dermatology and Skin Diseases (34 papers), Acne and Rosacea Treatments and Effects (22 papers), Chemotherapy-related skin toxicity (22 papers), Health Systems, Economic Evaluations, Quality of Life (18 papers) and Skin Protection and Aging (17 papers). The work is most often cited by research in Dermatology (8.1k citations), Immunology (8.8k citations), Rheumatology (1.7k citations), Complementary and Manual Therapy (221 citations) and Pathology and Forensic Medicine (1.3k citations). Alexa B. Kimball has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Kim Papp, Kenneth B. Gordon, Shu Li, Craig L. Leonardi, Gregor B. E. Jemec, Newman Yeilding, Jack Resneck, Cynthia Guzzo, Andrew Blauvelt and Yuhua Wang. Their work appears in journals such as Journal of the American Academy of Dermatology, British Journal of Dermatology, Journal of the European Academy of Dermatology and Venereology, Journal of Investigative Dermatology and JAMA Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact